Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis

Journal of Orthopaedic Research

Volumn 25, Issue 10, 2007, Pages 1378-1388

  Tunyogi Csapo, Miklos ^a,b   Koreny, Tamas ^a,b   Vermes, Csaba ^a,b   Galante, Jorge O ^a   Jacobs, Joshua J ^a   Glant, Tibor T ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Chemokines; Fibroblast; Periprosthetic osteolysis; Proinflammatory cytokines; Wear debris

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOCYTE; OSTEOLYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEADY STATE; TISSUE STRUCTURE; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ARTHROPLASTY, REPLACEMENT; CELLS, CULTURED; CHEMOKINES; DRUG COMBINATIONS; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; JOINT PROSTHESIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE SIZE; PHAGOCYTOSIS; RNA, MESSENGER; SYNOVIAL MEMBRANE; TITANIUM;

EID: 34948894428     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20449     Document Type: Article

References (50)

1. Goldring SR, Schiller AL, Roelke M, et al. 1983. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg [Am] 65-A:575-584.
2. Santavirta S, Konttinen YT, Bergroth V, et al. 1990. Aggressive granulomatous lesions associated with hip arthroplasty. J Bone Joint Surg [Am] 72-A:252-258.
3. Goodman SB, Knoblich G, O'Connor M, et al. 1996. Heterogeneity in cellular and cytokine profiles from multiple samples of tissue surrounding revised hip prostheses. J Biomed Mater Res 31:421-428.
4. Glant TT, Jacobs JJ, Mikecz K, et al. 1996. Particulate-induced, prostaglandin- and cytokine-mediated bone resorption in an experimental system and in failed joint replacements. Am J Ther 3:27-41.
5. Friedman RJ, Black J, Galante JO, et al. 1993. Current concepts in orthopaedic biomaterials and implant fixation. J Bone Joint Surg [Am] 75-A:1086-1109.
6. Yao J, Cs-Szabó G, Jacobs JJ, et al. 1997. Suppression of osteoblast function by titanium particles. J Bone Joint Surg [Am] 79-A:107-112.
7. Jacobs JJ, Roebuck KA, Archibeck M, et al. 2001. Osteolysis: basic science. Clin Orthop 393:71-77.
8. Glant TT, Jacobs JJ, Molnár G, et al. 1993. Bone resorption activity of particulate-stimulated macrophages. J Bone Miner Res 8:1071-1079.
9. Miyanishi K, Trindade MC, Ma T, et al. 2003. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macorphages by orthopaedic biomaterial particles. J Bone Miner Res 18:1573-1583.
10. Spanogle JP, Miyanishi K, Ma T, et al. 2006. Comparison of VEGF-producing cells in periprosthetic osteolysis. Biomaterials 27:3882-3887.
11. Glant TT, Yao J, Jacobs JJ. 1996. Induction of bone resorbing agents by titanium particulates: responses of macrophages, fibroblasts and osteoblasts in vitro. In: Brown SA, Lemons JE, editors. Medical applications of titanium and its alloys: the material and biological issues. ASTM STP 1272. West Conshohocken, PA: American Society for Testing and Materials, p 333-345.
12. Yao J, Glant TT, Lark MW, et al. 1995. The potential role of fibroblasts in periprosthetic osteolysis: fibroblast response to titanium particles. J Bone Miner Res 10:1417-1427.
13. Shanbhag AS, Jacobs JJ, Black J, et al. 1997. Effects of particles on fibroblast proliferation and bone resorption in vitro. Clin Orthop 342:205-217.
14. Wei X, Zhang X, Zuscik MJ, et al. 2005. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res 20:1136-1148.
15. Koreny T, Tunyogi-Csapo M, Gal I, et al. 2006. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 54:3221-3232.
16. Vermes C, Roebuck KA, Chandrasekaran R, et al. 2000. Particulate wear debris activates protein tyrosine kinases and nuclear factor-kappa B which downregulates type I collagen synthesis in human osteoblasts. J Bone Miner Res 15:1756-1765.
17. Maloney WJ, Smith RL, Castro F, et al. 1993. Fibroblast response to metallic debris in vitro. Enzyme induction, cell proliferation, and toxicity. J Bone Joint Surg [Am] 75-A:835-844.
18. Manlapaz M, Maloney WJ, Smith RL. 1996. In vitro activation of human fibroblasts by retrieved titanium alloy wear debris. J Orthop Res 14:465-472.
19. Ninomiya JT, Struve JA, Stelloh CT, et al. 2001. Effects of hydroxyapatite particulate debris on the production of cytokines and proteases in human fibroblasts. J Orthop Res 19:621-628.
20. Sakai H, Jingushi S, Shuto T, et al. 2002. Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. Ann Rheum Dis 61:103-109.
21. Horiki M, Nakase T, Myoui A, et al. 2004. Localization of RANKL in osteolytic tissue around a loosened joint prosthesis. J Bone Miner Metab 22:346-351.
22. Yang SY, Nasser S, Markel DC, et al. 2005. Human periprosthetic tissues implanted in severe combined immunodeficient mice respond to gene transfer of a cytokine inhibitor. J Bone Joint Surg [Am] 87:1088-1097.
23. Robinson CJ, Stringer SE. 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114:853-865.
24. Dvorak HF. 2005. Angiogenesis: update 2005. J Thromb Haemost 3:1835-1842.
25. Malemud CJ. 2007. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 375:10-19.
26. Jiranek WA, Machado M, Jasty M, et al. 1993. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg [Am] 75-A:863-879.
27. Goodman SB, Huie P, Song Y, et al. 1998. Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. J Bone Joint Surg [Br] 80:531-539.
28. Polverini PJ. 1995. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 6:230-247.
29. Ren WP, Markel DC, Zhang R, et al. 2006. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials 30:5161-5169.
30. Ren W, Zhang R, Markel DC, et al. 2007. Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis. J Rheumatol 34:27-35.
31. Wood J, Bonjean K, Ruetz S, et al. 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061.
32. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
33. Chiba J, Schwendeman LJ, Booth RE Jr, et al. 1994. A biochemical, histologic, and immunohistologic analysis of membranes obtained from failed cemented and cementless total knee arthroplasty. Clin Orthop 299:114-124.
34. Santavirta S, Xu JW, Hietanen J, et al. 1998. Activation of periprosthetic connective tissue in aseptic loosening of total hip replacements. Clin Orthop 352:16-24.
35. Goodman SB, Huie P, Song Y, et al. 1994. Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. Clin Orthop Rel Res 299:114-124.
36. Sabokbar A, Itonaga I, Sun SG, et al. 2005. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. J Orthop Res 23:511-519.
37. Pap T, Muller-Ladner U, Gay RE, et al. 2000. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2:361-367.
38. Suzuki J, Ikeda T, Kuroyama H, et al. 2004. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 314:1021-1027.
39. Lee J-M, Salvati EA, Betts F, et al. 1992. Size of metallic and polyethylene debris in failed cemented total hip replacements. J Bone Joint Surg [Br] 74-B:380-384.
40. Shanbhag AS, Jacobs JJ, Glant TT, et al. 1994. Composition and morphology of wear debris in failed uncemented total hip replacement arthroplasty. J Bone Joint Surg [Br] 76-B:60-67.
41. Maloney WJ, Smith RL, Schmalzried TP. 1995. Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg [Am] 77-A:1301-1310.
42. Udagawa N, Kotake S, Kamatani N, et al. 2002. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4:281-289.
43. Neufeld G, Cohen T, Gengrinovitch S, et al. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22.
44. Sabokbar A, Kudo O, Athanasou NA. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 21:73-80.
45. Niida S, Kaku M, Amano H, et al. 1999. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190:293-298.
46. Jell GM, Al Saffar N. 2001. Does a pro-angiogenic state exist in the bone-implant interface of aseptically loosened joint prosthesis? J Mater Sci Mater Med 12:1069-1073.
47. Henriksen K, Karsdal M, Delaisse JM, et al. 2003. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast Chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278:48745-48753.
48. Min JK, Kim YM, Kim YM, et al. 2003. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 278:39548-39557.
49. Haynes DR, Crotti TN, Potter AE, et al. 2001. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg [Br] 83-B:902-911.
50. Mandelin J, Li TF, Liljestrom M, et al. 2003. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg [Br] 85-B:1196-1201.